ClaimsDemis Hassabis

“But knowing the structure of a protein is only one small part of the drug discovery process.”

Demis Hassabis, CEO Google DeepMind, interviewee 10 April 2026 HUGE Conversations w/ Google DeepMind CEO Demis Hassabis (Transcript) (The Singju Post)

Factual Science and research methods

Knowing a protein's structure is only one small part of the drug discovery process.

Unresolvable The public record could not settle it.

Factual: Statements about the present or the past, checked against the record: did they hold up?

Reasoning

'One small part' is a vague evaluative judgement with no clear test.

Cite this claim

Demis Hassabis, “Knowing a protein's structure is only one small part of the drug discovery process.” (said 10 April 2026). Verdict: unresolvable. Reliability API, claim c_45868c59fbda, method 0.1.0+c876030c, dataset release v1.1.2. https://epistacklabs.com/claims/c_45868c59fbda

This claim is in dataset release v1.1.2, with the same verdict.

Reply to this claim

For Demis Hassabis, or someone speaking for them: a correction or counter-evidence. Replies are read before anything is shown; an approved reply shows your name, role, date, statement and link. Your email address is never shown and is deleted 30 days after the decision (privacy).

More factual claims by Demis Hassabis

  1. Mostly true Factual 10 April 2026
    “what’s important about them is their 3D structure.”

    A protein's 3D structure is what determines, or partially determines, its function.

  2. Resolved true Factual 10 April 2026
    “So over 3 million scientists are now using AlphaFold.”

    Over 3 million scientists are now using AlphaFold.

  3. Resolved true Factual 10 April 2026
    “Only about 10% of drugs actually get through all the clinical stages.”

    Only about 10% of drugs get through all the clinical stages.

  4. Mostly true Factual 25 November 2025
    “The AlphaFold Server is empowering non-commercial researchers globally to harness this technology, accelerating their ability to formulate and test new hypotheses.”

    The AlphaFold Server is available to non-commercial researchers globally for predicting structures and interactions.

  5. Mostly true Factual 25 November 2025
    “Our AlphaProteo model can design novel, high-strength protein binders that target diverse molecules – including those associated with cancer and diabetes.”

    AlphaProteo can design novel, high-strength protein binders targeting diverse molecules, including ones associated with cancer and diabetes.

All of them

Verdicts are made automatically; how verdicts are made.